TICKERNERD
Menu
PRMEPRMEHealthcare · Biotechnology

PRME Stock Forecast: Prime Medicine, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$3.13
−6.57% on the day

The 14 Wall Street analysts covering Prime Medicine, Inc. hold a median 12-month price target of $7 — +123.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 36 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$567.7M
Ticker Nerd rank
36 / 100
Median analyst target
$7.00
Analysts covering
14
Revenue$1.2M+3.5% y/y
Operating income−$43.3M
Net income−$42.1M
Free cash flow−$41.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.6%
1M
−4.0%
YTD
−9.8%
1Y
−23.3%
From 52W high
−53.1%
From 52W low
+15.9%
$2.70
$6.67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PRME stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Prime Medicine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
36 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
63
Growth
62
Issuance
55
Size
52
Revisions
52
Momentum
35
Quality
33
Value
33
Volatility
13

Accruals (63): Reported profit is backed by cash, and the company is not expanding recklessly.

Volatility (13): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PRME stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PRME, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26PRMEHigh $11.00Median $7.00Low $4.25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
11 Buy3 Hold0 Sell
Low $4.25Median $7.00High $11.00

The green dot is the last close — the median target sits +123.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
25 Aug 2026Chardan CapitalMaintainsBuy$7.00
19 Aug 2026BMO CapitalInitiatesOutperform$9.00
10 Aug 2026HC Wainwright & Co.ReiteratesBuy—
10 Aug 2026HC Wainwright & Co.ReiteratesBuy$8.00
29 June 2026HC Wainwright & Co.UpgradeBuy$8.00
29 June 2026HC Wainwright & Co.UpgradeBuy—
12 Mar 2026OppenheimerInitiatesOutperform—
23 Dec 2025LifeSci CapitalInitiatesOutperform—
11 Nov 2025CitigroupMaintainsNeutral—
10 Nov 2025Chardan CapitalMaintainsBuy—
12 Aug 2025CitigroupMaintainsNeutral—
8 Aug 2025Chardan CapitalMaintainsBuy—
27 May 2025CitigroupDowngradeNeutral—
20 May 2025HC Wainwright & Co.DowngradeNeutral—
20 May 2025JMP SecuritiesMaintainsMarket Outperform—
20 May 2025JP MorganDowngradeNeutral—
19 May 2025Chardan CapitalMaintainsBuy—
20 Mar 2025Chardan CapitalMaintainsBuy—
19 Mar 2025HC Wainwright & Co.ReiteratesBuy—
4 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRME appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PRME vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Prime Medicine, Inc. returned −23.3% against +17.5% for the S&P 500, dividends included.

PRME vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Oct 25Jan 26Apr 26Jul 26PRMES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PRME analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
7
Analysts cutting
3
Fundamentals

Prime Medicine, Inc. (PRME) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.3×

Cheaper than 86% of US stocks

Price / sales
139.4×

Cheaper than 3% of US stocks

Price / book
13.9×

Cheaper than 7% of US stocks

EV / EBITDA
−3.0×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
3.5%

Higher than 35% of US stocks

Earnings growth (YoY)
3.5%

Higher than 40% of US stocks

Gross margin
—
Operating margin
−3750.9%

Higher than 3% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−373.3%

Higher than 4% of US stocks

Return on assets
−46.5%

Higher than 9% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Prime Medicine, Inc. (PRME) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Prime Medicine, Inc. has a market value of $567.7M and an enterprise value of $574.2M.

  • Revenue in the twelve months to 30 June 2026: $4.1M. The latest quarter grew 3.5% year on year.

  • Net income over the same four quarters: −$187.9M, a −4613.1% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$156.8M.

  • Shares outstanding: 180.7M.

  • Trailing P/E: −2.3×; forward P/E: −3.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Prime Medicine, Inc. employs 146 people — $28K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

PRME vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PRMEPrime Medicine, Inc.$567.7M
36
CTNMContineum Therapeutics, Inc.$574.4M
59
SCTXScribe Therapeutics, Inc.$561.0M
1
RGNXREGENXBIO, Inc.$557.1M
53
ALLOAllogene Therapeutics, Inc.$589.7M
78
ASMBAssembly Biosciences, Inc.$590.6M
89
OABIOmniAb, Inc.$591.7M
95

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Prime Medicine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PRME news & analysis

Prime Medicine to Participate in Upcoming Investor Conferences

GlobeNewsWire · 3 Sept 2026neutral

Prime Medicine, Inc. announced that its management will participate in three upcoming investor conferences, beginning with 1x1 meetings at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, in Boston, MA.

Why it matters — A PRME watcher would care because the company's leadership will be presenting to investors at multiple conferences, offering opportunities for exposure to the investment community.

Prime Medicine: Soon In The Clinic

Seeking Alpha · 15 Aug 2026positive

Prime Medicine, described as trading at a $548M valuation, is highlighted for its broad gene-editing pipeline targeting five indications in liver, lung, and immunology/oncology. Recent IND/CTA clearances, RMAT designation, and patent wins are cited as clinical and strategic momentum despite a 54% decline from 52-week highs.

Why it matters — PRME watchers would care because the piece highlights recent regulatory and patent progress for the company's preclinical gene-editing pipeline, even as the stock has fallen sharply from its highs.

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 6 Aug 2026neutral

Prime Medicine reported a Q2 loss of $0.24 per share, in line with the Zacks Consensus Estimate and narrower than the $0.41 per share loss recorded a year ago.

Why it matters — The in-line loss being narrower than the prior year may interest PRME watchers as a sign of improving quarterly performance.

Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Zacks Investment Research · 30 July 2026negative

Zacks Investment Research reported that Prime Medicine, Inc. (PRME) lacks the necessary combination of factors for a likely earnings beat in its upcoming Q2 report. The article advises investors to prepare with key expectations ahead of the release.

Why it matters — PRME watchers would monitor this ahead of the Q2 earnings release because a potential negative earnings report could impact investor sentiment and the stock's near-term performance.

FAQ

Frequently asked questions about PRME stock

What is the PRME stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Prime Medicine, Inc. have a median 12-month price target of $7, with estimates ranging from $4.25 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PRME stock a buy right now?

Of the 14 analysts covering Prime Medicine, Inc., 11 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Prime Medicine, Inc. 36 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PRME?

As at 12 Sept 2026, Prime Medicine, Inc. ranks 36 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (63 of 100).

Will PRME stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +123.6% from the last close, and Ticker Nerd's factor model ranks Prime Medicine, Inc. 36 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PRME stock forecast for 2030?

No analyst covering Prime Medicine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRME are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.25 to $11 over the next 12 months.

How has PRME stock performed over the past year?

Prime Medicine, Inc. returned -23.3% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Prime Medicine, Inc. do?

Prime Medicine, Inc. is a biotechnology company focused on developing genetic medicines through its Prime Editing platform, a gene-editing technology designed to make precise changes to DNA.

What is the latest news on PRME?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Prime Medicine to Participate in Upcoming Investor Conferences". Prime Medicine, Inc. announced that its management will participate in three upcoming investor conferences, beginning with 1x1 meetings at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026, in Boston, MA.

Company

About Prime Medicine, Inc.

Prime Medicine, Inc. is a biotechnology company focused on developing genetic medicines through its Prime Editing platform, a gene-editing technology designed to make precise changes to DNA. The company is building therapies intended to address diseases caused by defined genetic alterations, with research programs spanning hematology, immunology and oncology, liver, lung, ocular, and neuromuscular conditions. Its current work centers on investigational, pre-commercial product candidates and platform capabilities that support targeted genetic correction across multiple tissues and disease areas. Prime Medicine, Inc. plays a specialized role in the broader genetic medicines market by advancing next-generation editing approaches aimed at expanding the reach of precision therapeutics for serious inherited and acquired diseases.

CEO Dr. Allan Reine M.D. · 146 employees · United States · https://primemedicine.com